February 11, 2022 5:08pm

Increased concerns about Russia taking military action against Ukraine.

Pre-open Indications: 3 Hits and 3 Miss

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

Who else is tracking a broad grouping of cell and gene therapy equities – with facts supported by real numbers?

The week in review …

The Dow closed DOWN -503.53 points (-1.43 %); the S&P closed DOWN -85.44 points (-1.90%) while the Nasdaq closed DOWN -394.49 points (2.78%)

 

Henry’omics:

Indexes resumed its decline at midday Friday as Treasury yields reversed higher.

Small caps led the stock market as the Russell 2000 rose 0.3%. The Russell has outperformed this week, up more than 3%.

A University of Michigan survey showed U.S. consumer sentiment fell to its lowest level in more than a decade in early February amid expectations that inflation would continue to rise in the near term.

The CBOE volatility index, also known as the fear gauge, was up for a second straight session after hitting its lowest level since mid-January on Wednesday.

 

RegMed Investors’ (RMi) pre-open: “put a cork in the cell and gene therapy bottle before trading evaporates the contents. Another wild Friday.” …  https://www.regmedinvestors.com/articles/12297

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Friday opened positive at 17 up/14 downs, 3 flats and 1 acquired, turned negative at the mid-day at 14/20 and 1 acquired, ending with a negative close of 3/32 and 1 acquired;
  • Thursday opened negative at 10 up/21 downs, 2 flats and 1 acquired, flipped positive at the mid-day at 20/12, 2 flats and 1 acquired, ending with a severe negative close of 5/28, 1 flat and 1 acquired;
  • Wednesday opened positive at 31 up/1 downs, 2 flats and 1 acquired, stayed positive at the mid-day at 32/1, 1 flat and 1 acquired, ending with a positive close of 31/3 and 1 acquired;
  • Tuesday opened negative at 16 up/17 downs, 1 flat and 1 acquired, slipped further negative at the mid-day at 10/24 and 1 acquired, ending with a negative close of 14/19, 1 flat and 1 acquired;
  • Monday opened positive at 33 up/1 downs and 1 acquired, stayed positive at the mid-day at 30/4, 1 flat and 1 acquired, ending with a positive close of 29/4, 1 flat and 1 acquired;

 

Pre-open indications: 3 Hits < Applied Genetic Technologies (AGTC -$0.24), Biostage (BSTG -$0.02)> 3 MISS < CRISPR Therapeutics (CRSP -$2.50), Editas Medicine (EDIT -$1.16), Intellia Therapeutics (NTLA -$3.36)>

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares trading down -$0.02 with 1,739 shares traded after Thursday’s +$0.60 with 2,841 shares traded after Wednesday’s down -$0.61 (was as low as -$1.09) with 4,030 shares traded after Tuesday’s +$0.05 with 1,293 shares traded after Monday’s +$0.55 with 2,311 shares traded,

  • The previous Friday’s +$0.22 with 305 shares traded, Thursday’s flat ($0.00) with 3 shares traded, Wednesday’s down -$0.53 with 502 shares traded, Tuesday’s +$0.40 with 1,088 shares after Monday’s 11 shares traded after Friday’s +$0.05 with 3,225 shares traded after Thursday’s +$0.24 with 10,073 - double the mornings 5,030 shares traded after last Wednesday’s diving to -$0.00 with 7,796 shares trading after appreciating +$0.35 (after dropping mid-day -$0.07 – such sarcasm after miraculous jump) and the previous Tuesday’s +$0.31 with 2,794 shares traded.

 

Key Metrics:

  • Friday - Sector volume was LOW with 2 of the 3-upside having higher than the 3-month average volume with LOW volume of 3 of 32-downside having higher than the 3-month average volume
  • Thursday - Sector volume was LOW with 3 of the 5-upside having higher than the 3-month average volume with LOW volume of 12 of 28-downside having higher than the 3-month average volume
  • Wednesday - Sector volume was LOW with 9 of the 31-upside having higher than the 3-month average volume with LOW volume of 1 of 3-downside having higher than the 3-month average volume
  • Tuesday - Sector volume was LOW with 2 of the 14-upside having higher than the 3-month average volume with LOW volume of 5 of 19-downside having higher than the 3-month average volume
  • Monday - Sector volume was LOW with 4 of the 29-upside having higher than the 3-month average volume with LOW volume of 1 of 4-downside having higher than the 3-month average volume;

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday the IBB closed down -1.31% and XBI closed down -1.07%
  • Thursday the IBB closed down -2.44% and XBI closed down -2.98%
  • Wednesday the IBB closed up +4.65% and XBI closed up +2.70%
  • Tuesday the IBB closed down -0.07% and XBI closed down -0.33%
  • Monday   the IBB closed up +0.77% and XBI closed up +2.71%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was up +3.45 points or +14.43% at 27.36
  • Thursday was up +3.95 points or +19.79% at 23.91
  • Wednesday was down -1.48 points or -6.90% at 19.96
  • Tuesday was down -1.31 points or -5.86 at 21.52
  • Monday was down -0.34 points or -1.46% at 22.88

 

Jumping with share pricing momentum (3 of 3):

  • ReNeuron (RENE.L +$7.00),
  • Ultragenyx (RARE +$1.51),
  • Bellicum Pharmaceuticals (BLCM +$0.02),

Hammered in today’s market (10 of 32):

  • Intellia Therapeutics (NTLA -$3.36),
  • CRISPR Therapeutic (CRSP -$2.50),
  • BioLife Solutions (BLFS -$1.37),
  • Editas Medicine (EDIT -$1.16),
  • Ionis Pharmaceuticals (IONS -$0.66),
  • Regenxbio (RGNX -$0.61),
  • AxoGen (AXGN -$0.44),
  • Sage Therapeutics (SAGE -$0.35),
  • bluebird bio (BLUE -$0.34),
  • Chinook Therapeutics (KDNY -$0.32),

Closing Flat:

  • 1 -Stemline Therapeutics (STML) – acquired

 

February, Q1/2022:

  • Friday closed negative with 3 incliner, 32 decliners and 1 acquired
  • Thursday closed negative with 5 incliner, 28 decliners, 1 flat and 1 acquired
  • Wednesday closed positive with 31 incliner, x decliners and 1 acquired
  • Tuesday closed negative with 14 incliners, 19 decliners, 1 flat and 1 acquired
  • Monday (2/7) closed positive with 29 incliners, 4 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: The sector struggled and felt the pain after pain following the gain again after alternate session reverses as share pricings “lunged” to the down-side again as I had stated “the algorithms were p to pitching”.

The race to the weekend …

Friday’s “sprinters” were ReNeuron (RENE.L), Ultragenyx (RARE) and Bellicum Pharmaceuticals (BLCM) while losers were Intellia Therapeutics (NTLA), Alnylam Pharmaceuticals (ALNY) BioLife Solutions (BLFS), CRISPR Therapeutics (CRSP), Chinook therapeutics (KDNY) and AxoGen (AXGN).

Thursday’s “hurdlers” were Biostage (BSTG) although pumped volume and promoted share pricing, Global Blood Therapeutics (GBT), BioLife Solutions (BLFS) and Applied Genetic Technologies (AGTC) while more that a few tripped on the track: Alnylam Pharmaceuticals (ALNY), Ultragenyx (RARE), CRISPR Therapeutics (CRSP) and Sage Therapeutics (SAGE).

Wednesday’s “jumpers” were Ultragenyx Pharmaceuticals (RARE), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and ReNeuron (RENE.L) with Biostage (BSTG) diving following …

Tuesday’s ReNeuron (RENE.L) race to the upside after feeling the grit of laying in the dirt of the downside while trading up again were Sage Therapeutics (SAGE and Global Blood Therapeutics (GBT) while the few down-trodden were Intellia therapeutics (NTLA) after

Monday’s up and Editas Medicine (EDIT) and CRISPR Therapeutics (CRSP), along with losers BioLife Solutions (BLFS) and Precigen (PGEN).

Investors will be watching earnings reports this week; Q4 and end-of-year earnings are about to be made aware of” more than even I thought.          

  • Applied Genetic Technologies (AGTC) on Monday, 2/14
  • AxoGen AXGN) –Tuesday, 2/22
  • Vericel (VCEL) –Thursday, 2/24,

Algorithms, hedge funds and traders continue to punish and … then push the cell and gene therapy stocks as valuations “creep” up.

WHY do I keep analyzing Biostage (BSTG): I WAS there to experience the lack of investor prerogatives and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.